To investigate if R-RAS2 is downstream of CD44 mediating BC cell migration and metastasis, we first determined that R-RAS2 knockdown in CBM-MBC21 cells did not alter the expression of CD44, suggesting that all subsequent effects of reducing R-RAS2 expression were not due to reduction of the expression of the receptor (Suppl. Here, RRAS2 is linked to breast cancer.